Scandion Oncology A/S Market Cap ($103.58K)
Market Cap & Net Worth: Scandion Oncology A/S (SCOL)
Scandion Oncology A/S market cap. Scandion Oncology A/S (ST:SCOL) has a market capitalization of $103.58K (Skr962.52K) as of November 5, 2026. Listed on the ST stock exchange, this Sweden-based company holds position #31516 globally and #745 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Scandion Oncology A/S's stock price Skr0.00 by its total outstanding shares 234762000 (234.76 Million). Also see Scandion Oncology A/S cash conversion from operations for how efficiently the company converts equity into cash flow.
Scandion Oncology A/S Market Cap History (2021–2025)
Scandion Oncology A/S market cap history from 2021 to 2025. Data shows change from $312.77 Million to $103.58K (-84.99% CAGR). Check Scandion Oncology A/S share price for real-time trading data and today's change.
Scandion Oncology A/S Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Scandion Oncology A/S's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore SCOL year-over-year net asset growth to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of SCOL by Market Capitalization
Companies near Scandion Oncology A/S in the global market cap rankings as of November 5, 2026. Also see Scandion Oncology A/S (SCOL) total assets for a full breakdown of the balance sheet.
Key companies related to Scandion Oncology A/S by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #368 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #414 globally with a market cap of $68.22 Billion USD ( AU$96.41 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $530.76 |
| #368 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $973.36 |
| #414 | CSL Ltd | AU:CSL | $68.22 Billion | AU$198.72 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $228.44 |
Market Capitalization of Scandion Oncology A/S (2021–2025)
Market capitalization of Scandion Oncology A/S from 2021 to today. Between 2021 and today, Scandion Oncology A/S's market cap moved from $312.77 Million to $ 103.58K, with a yearly change of -84.99%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | Skr103.58K | -94.50% |
| 2024 | Skr1.88 Million | -98.14% |
| 2023 | Skr100.93 Million | +42.68% |
| 2022 | Skr70.74 Million | -77.38% |
| 2021 | Skr312.77 Million | -- |
End of Day Market Cap According to Different Sources
On Jul 10th, 2026 the market cap of Scandion Oncology A/S was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $103.58K USD |
| MoneyControl | $103.58K USD |
| MarketWatch | $103.58K USD |
| marketcap.company | $103.58K USD |
| Reuters | $103.58K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Scandion Oncology A/S
Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for tr… Read more